PubRank
Search
About
Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Clinical Trial ID NCT01044069
PubWeight™ 52.05
‹?›
🔗 Visit the ClinicalTrials.gov page for NCT01044069
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.
Sci Transl Med
2013
7.99
2
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.
Blood
2011
7.49
3
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
Sci Transl Med
2014
5.60
4
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.
Blood
2010
3.57
5
The basic principles of chimeric antigen receptor design.
Cancer Discov
2013
3.28
6
Antibody-modified T cells: CARs take the front seat for hematologic malignancies.
Blood
2014
2.84
7
Gene-engineered T cells for cancer therapy.
Nat Rev Cancer
2013
2.07
8
Chimeric antigen receptor therapy for cancer.
Annu Rev Med
2013
1.94
9
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.
Nat Rev Clin Oncol
2013
1.91
10
Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies.
Int J Hematol
2013
1.64
11
CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia.
PLoS One
2013
1.19
12
Engineered T-cell therapy shows efficacy in blood cancer.
Nat Biotechnol
2011
1.17
13
Driving CAR T-cells forward.
Nat Rev Clin Oncol
2016
1.09
14
Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells.
Discov Med
2010
0.99
15
Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells.
Front Immunol
2013
0.98
16
Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies.
Cancer Gene Ther
2015
0.97
17
CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL).
Ther Adv Hematol
2015
0.95
18
Driving CAR-based T-cell therapy to success.
Curr Hematol Malig Rep
2014
0.89
19
Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches.
Leukemia
2014
0.86
20
Clinical development of gene therapy: results and lessons from recent successes.
Mol Ther Methods Clin Dev
2016
0.85
21
Synthetic biology in cell-based cancer immunotherapy.
Trends Biotechnol
2015
0.84
22
Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells.
ISRN Oncol
2012
0.84
23
Genetically engineered T cells for the treatment of cancer.
J Intern Med
2013
0.83
24
Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia.
Adv Hematol
2011
0.79
25
Cellular therapies in acute lymphoblastic leukemia.
Hematol Oncol Clin North Am
2011
0.78
26
Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors.
World J Stem Cells
2015
0.78
27
Using gene therapy to manipulate the immune system in the fight against B-cell leukemias.
Expert Opin Biol Ther
2015
0.77
28
Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.
Pediatr Blood Cancer
2015
0.75
Next 100